BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35797633)

  • 21. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
    Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.
    Ulaner GA
    Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
    Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
    J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Predictive Value of Early Changes in
    He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
    Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of a new diagnostic tool in deep infiltrating endometriosis: Positron emission tomography-computed tomography with 16α-[18F]fluoro-17β-estradiol.
    Cosma S; Salgarello M; Ceccaroni M; Gorgoni G; Riboni F; La Paglia E; Danese S; Benedetto C
    J Obstet Gynaecol Res; 2016 Dec; 42(12):1724-1733. PubMed ID: 27558211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with 18F-FDG and 18F-FES.
    Hołody Ł; Kunikowska J; Braziewicz J
    Nucl Med Rev Cent East Eur; 2018; 21(2):113-114. PubMed ID: 29956818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Feasibility Study of
    Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
    J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
    Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
    J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biodistribution of
    Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
    Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
    Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
    Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
    Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP).
    Tewson TJ; Mankoff DA; Peterson LM; Woo I; Petra P
    Nucl Med Biol; 1999 Nov; 26(8):905-13. PubMed ID: 10708304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-
    Ulaner GA; Mankoff DA; Clark AS; Fowler AM; Linden HM; Peterson LM; Dehdashti F; Kurland BF; Mortimer J; Mouabbi J; Moon DH; de Vries EGE
    J Nucl Med; 2023 Mar; 64(3):351-354. PubMed ID: 36863779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.